Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Uveal Melanoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

pembrolizumab 16Cyclophosphamide 9Nivolumab 7atezolizumab 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5cabozantinib 4Trastuzumab 4budigalimab 3Ipilimumab 3Interleukin-2 3Cisplatin 3Capecitabine 3Albumin-Bound Paclitaxel 3spartalizumab 2sargramostim 2poly ICLC 2palbociclib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2X-Rays 2Sunitinib 2Paclitaxel 2Irinotecan 2Interleukin-12 2Immunoglobulin G 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Rose Bengal × Breast × Clear all
NCT00986661 2022-11-02

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
78 enrolled
BreastDermatologicEndocrineGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡